Condition
MDS-EB
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Unknown2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05933070Phase 1Terminated
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
NCT04599426Phase 1UnknownPrimary
Allogenic NK Cell Transfusion Azacitidine MDS-EB
NCT04216355Phase 2UnknownPrimary
Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT
Showing all 3 trials